Fat molecules may limit damage to nerve cells in ALS, study finds
Fat molecules called polyunsaturated fatty acids, or PUFAs, can help lessen nerve damage in amyotrophic lateral sclerosis (ALS), according…
Articles by Marisa Wexler, MS
Results published for first 4 drugs in HEALEY trial; 2 to be tested further
Four experimental treatments for amyotrophic lateral sclerosis (ALS) have been tested in the HEALEY ALS platform trial and two,…
Sleep problems may develop years before ALS motor symptoms: Study
Sleep problems may become evident in people with amyotrophic lateral sclerosis (ALS) several years before the characteristic motor symptoms…
IFB-088 slows disease progression in bulbar-onset ALS trial
Oral therapy IFB-088 (icerguastat) was safe and significantly slowed disease progression in certain people with amyotrophic lateral sclerosis (ALS),…
AMT-162 gene therapy trial for SOD1-ALS set for next dose group
uniQure is planning to start enrolling patients in a second dose group as part of a clinical trial testing…
Diabetes, high cholesterol linked with lower risk of developing ALS
People with diabetes or high cholesterol may be less likely to develop amyotrophic lateral sclerosis (ALS) or other motor…
Feeding tube best placed before major weight loss with ALS: Study
People with amyotrophic lateral sclerosis (ALS) who get a feeding tube placed after losing a lot of weight are…
HEALEY ALS trial to allow longer follow-up, blood cell collection
The HEALEY ALS platform trial, which is simultaneously testing multiple potential treatments for amyotrophic lateral sclerosis (ALS), is…
FDA outlines steps to consider accelerated approval of CNM-Au8
The U.S. Food and Drug Administration (FDA) signaled that it may be willing to consider granting accelerated approval to…
Brain scans may predict ALS risk in C9ORF72 mutation carriers
People with mutations in the C9ORF72 gene who develop amyotrophic lateral sclerosis (ALS) show signs of damage to certain…